Side-by-side · Research reference
TestagenvsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/41 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
Testagen
Vilon
Primary target
Testicular tissue; proposed nuclear DNA interaction
Immune cell differentiation pathways, chromatin modification
Pathway
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
Unknown — no HPG axis data
Unknown — no HPA/HPG axis data
Origin
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
—
—
02Dosage Protocols
Parameter
Testagen
Vilon
Typical protocol (anecdotal)
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
—
Frequency
Once daily or alternate days
Unknown — literature does not specify chronic administration protocols
Cycle length
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
—
Route
Subcutaneous
Likely SQ or oral (Khavinson school uses both); no published ROA validation
Reconstitution
Sterile water or bacteriostatic saline
—
Half-life
Unknown — likely minutes (short peptide)
Not published — dipeptides typically <10 min plasma t½
Standard dose
—
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Duration
—
Not characterised in humans
04Side Effects & Safety
Parameter
Testagen
Vilon
Injection site reactions
Erythema, mild irritation (potential)
—
Systemic effects
Unknown — no human safety data
—
Hormonal impact
No published data on testosterone, LH, FSH effects
—
Long-term safety
Unknown — no long-term studies
—
Human safety data
—
Absent from PubMed-indexed literature
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formation
—
Not reported; dipeptides generally low immunogenicity
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
Testagen
- ·Active testicular malignancy
Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
Testagen
Vilon
1. Reconstitution
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Timing
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Storage
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
5. Cycle protocol
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.
—
06Stack Synergy
Testagen
— no documented stacks
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation